70 results
Advancing the treatment of uncontrolled hypertension with ultrasound renal denervation
17 May 2022 – From EuroPCR 2022
This EuroPCR 2022 session, which covers the latest clinical evidence around catheter-based ultrasound renal denervation, will also enable you to appreciate the distinct features of this approach, to understand perspectives on patient selection and patient preference, and to learn how to introduce and establish interventional hypertension therapy.
EuroPCR 2022 Hotlines / Late-Breaking Trials in hypertension management: SPYRAL-HTN ON MED, radiance HTN SOLO and TRIO, and more!
17 May 2022 – From EuroPCR 2022
Find out more about various studies & registries in hypertension management! Blood pressure and MACE reductions after renal denervation: 3-year GSR results, patient-level pooled analysis of ultrasound RDN in radiance-HTN SOLO and Trio, and SPYRAL-HTN ON MED 3 year data.
Hypertension management in 2022: Latest data on renal denervation - EuroPCR 2022
17 May 2022
On the occasion of World Hypertension Day, Felix Mahfoud speaks about the value of renal denervation, including the latest data and what we can learn about renal denervation at EuroPCR 2022.
Author
PCRonline @ ACC 2022 Scientific Sessions
29 Mar 2022
Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2022 Scientific Sessions #ACC22.
3-year Efficacy Outcomes From the Spyral Htn-on Med Pilot Study: Long Term Effect of Renal Denervation On Blood Pressure Reduction in Patients on Antihypertension Medications
22 Mar 2022
Ali Nazmi Calik provides his take on the long-term results of the SPYRAL HTN-ON MED trial which demonstrated the durable efficacy and safety of RDN in patients who are already on one to three antihypertensive drugs.
Author
RADIANCE-HTN: Six-Month Outcomes of a Randomized Trial of Renal Denervation Versus a Sham Procedure for Resistant Hypertension – Impact of Treatment-Blinded Medication Titration
04 Nov 2021
Panos Xaplanteris review the RADIANCE-HTN Study, presented by Ajay Kirtane, an international randomized, sham-controlled clinical trial evaluating the safety and efficacy of renal denervation (RDN) in a population of treatment-resistant hypertensive patients.
Author
PCRonline @ TCT 2021 - Get the international perspective!
03 Nov 2021
Thanks to the contribution of a team of interventional cardiologists from around the globe, view the international perspective on Late-breaking Clinical Trials and Science released at TCT 2021 - check out the list here!
Delivering what matters: hypertension management with renal denervation and management of high bleeding risk patients undergoing complex PCI
08 Oct 2021 – From AICT-AsiaPCR 2021
Watch this session mainly focused on renal denervation to find out more about its latest evidence, to learn about its safety profile, and to review patient-centred clinical judgment and individualised treatment plans.
Renal denervation in the real-world: performance in high risk subgroups
05 Oct 2021 – From AICT-AsiaPCR 2021
After having evoked in particular the SPRAL HTN Global Clinical Program, the RDN consensus statements, the EHS position paper 2021, the ARDeC, and the STEP Trial, Tzung-Dau Wang shares his experience in using renal denervation to manage uncontrolled hypertension by illustrating his words with the case...
EuroPCR 2021 Hotlines / Late-Breaking Trials in renal denervation: EFFECTIVENESS
25 May 2021 – From EuroPCR 2021
Find out more about the EFFECTIVENESS trial regarding renal denervation.
